Navigation Links
Conseco Declines Partnership's Request for Board Seats; Review of Strategic Alternatives Underway
Date:3/17/2008

CARMEL, Ind., March 17 /PRNewswire-FirstCall/ -- Conseco, Inc. (NYSE: CNO) today announced that it is declining a request from Steel Partners II, L.P. to nominate two of its representatives to Conseco's board of directors. Conseco also announced that it has been reviewing strategic alternatives and has engaged the investment banking firm of Morgan Stanley as its strategic advisor.

Conseco CEO Jim Prieur said, "We share with Steel Partners, as well as our other shareholders, a common interest in taking actions that will increase the value of the company for shareholders. In that regard, we have been working with a major investment bank for several months regarding strategic alternatives and plans to maximize shareholder value for Conseco. We believe, and hope Steel Partners would concur, that we already are exploring courses of action suggested by them."

Steel Partners President Jack L. Howard asked Conseco on March 14 to nominate himself and Chief Executive Warren G. Lichtenstein to the board of directors. Steel Partners said their intention was to work with the company to engage an investment bank to assist Conseco in exploring alternatives to maximize shareholder value.

Conseco, Inc.'s insurance companies help protect working American families and seniors from financial adversity: Medicare supplement, long-term care, cancer, heart/stroke and accident policies protect people against major unplanned expenses; annuities and life insurance products help people plan for their financial futures. For more information, visit Conseco's web site at http://www.conseco.com.


'/>"/>
SOURCE Conseco, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
2. Hacker Joins Conseco as Senior Vice President and Treasurer
3. Tongson Joins Conseco as Senior Vice President, Corporate Actuarial
4. Conseco to Implement Systems and Operational Solution From Long Term Care Group
5. Conseco Reports Third Quarter Results
6. Conseco Sets Earnings Release Date
7. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
8. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
9. Conseco to Host Follow-Up Long-Term Care Conference Call
10. Pilot error declines as factor in airline mishaps
11. CDC Reports that Adult Smoking Declines Have Stalled; Elected Officials Should Step up Fight Against Tobacco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...alif., May 12 /PRNewswire/ -- Keck Graduate Instit...ommencement ceremony will feature,the graduation o..., Eric,Tan, and the unveiling of KGI,s first donat...ic,s achievement in becoming the,first graduate of...s senior,vice president for academic affairs, dean...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER, May ...(NASDAQ: CRME / TSX: COM) today announced that it ...r of 2008 on the afternoon of Tuesday, May 13,200...bcast at 4:30pm,Eastern (1:30pm Pacific) on that d...nce call, please dial 416-641-6117 or,866-299-6655...
(Date:5/12/2008)...Host Webcast Featuring Synchronized Slides at 5pm ...all/ -- NxStage Medical, Inc.,(Nasdaq: NXTM ), a ...ts,today announced its financial results for the ... the first quarter of 2008 were $31.0 million, com... and $29.9 million in the fourth,quarter of 2007. ...
(Date:5/12/2008)...ay 12 /PRNewswire-FirstCall/ - SXC Health Solution...vider of pharmacy benefits,management services and...,2007 Annual Meeting of Shareholders will be held ...4:30 p.m. Central Time at the Marriott Downtown, 5... presentation will be webcast live. To access the ...
Breaking Medicine News(10 mins):Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 2Health News:NxStage Medical Reports First Quarter 2008 Results 3Health News:NxStage Medical Reports First Quarter 2008 Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 5Health News:NxStage Medical Reports First Quarter 2008 Results 6Health News:NxStage Medical Reports First Quarter 2008 Results 7Health News:NxStage Medical Reports First Quarter 2008 Results 8Health News:NxStage Medical Reports First Quarter 2008 Results 9Health News:NxStage Medical Reports First Quarter 2008 Results 10Health News:NxStage Medical Reports First Quarter 2008 Results 11
... a disease that spreads through mosquitoes. Accord... health officials there has been an increase in th... 123 people are admitted in the hospital showing s...ever, severe arthralgia (joint pain), headache, ch...
...pound found in cannabis, also known as hashish or ...ntists after testing it on rats //. Yehoshua Maor...em, Israel, has created a synthetic version of a m...igerol, which has been shown to help in lowering b...
...he International Agency for Research on Cancer it ...women globally and resulted in the death of 400,00...d by the team, at Iceland's Decode Genetics it was...ARD1 variant increased the risk of breast cancer f...
... new study published in the Journal of Neurophysio...ic seizures by inducing rhythmical //electrical ac...n known as the hippocampus. The researchers found ...thm on chronically epileptic rats, they could redu...
Other Medicine News:Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
(Date:5/9/2008)...ire/ -- Many strong acting pain,medications have b...nd,vomiting with short-term use, and constipation ...atients to discontinue treatment, adding additiona... The novel investigational,medication tapentadol, ...elief for patients with fewer gastrointestinal sid...
(Date:5/9/2008)...ipeline cancer drug candidates, MELBOURNE, Austra...ed,(ASX: CYT) today announced that it has entered ... collaboration with Cancer Therapeutics CRC Pty,Lt...drug discovery pipeline,of kinase inhibitors, a cl...stest growing segments of the cancer drug market.,...
(Date:5/8/2008)...dical, Inc., the largest,privately held spinal imp...ader in motion preservation technology, today anno...)-C Cervical Artificial Disc IDE study. The,SECURE...n of the spine in,order to alleviate pain and rest...eatment of symptomatic cervical disc disease. A to...
(Date:5/8/2008)...ll/ -- Alpharma Inc. (NYSE: ALO ),a global speci...ts from,clinical trials that showed ALO-01 (EMBEDA...estered naltrexone hydrochloride) capsules,demonst...e liability,alongside a promising safety and effic... at the 27th Annual Scientific Session of the Amer...
Breaking Medicine Technology:New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Kristalose 28R 29 Offers Prescription Alternative to MiraLAX 28R 29 and Other PEG 3350 Products 12784 1Kristalose 28R 29 Offers Prescription Alternative to MiraLAX 28R 29 and Other PEG 3350 Products 12784 2Kristalose 28R 29 Offers Prescription Alternative to MiraLAX 28R 29 and Other PEG 3350 Products 12784 3Mayor Hula Hoops at City Council Meeting 12782 1Out of whack protein may boost Parkinsons 12778 1Out of whack protein may boost Parkinsons 12778 2VIDEO from Medialink and Siemens 3A NFL Stars Stress the Importance of a Healthy Heart 12773 1
...n-Americans with Family History of ESRD Are at Hig...ely ten percent of U.S.,adults have a family histo...dividuals appear to be at increased risk of develo... the April Journal of,the American Society of Neph...ore frequent in,African-Americans, who are also at...
...ORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ ...t results of the,Phase II trial of its novel oral ... be presented at the 2007 annual Scientific Sessio...ervention (i2),Summit, March 24-27 in New Orleans....eceptor Antagonist in Percutaneous Coronary,Interv...
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: